Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.